Vincent-Naulleau S, Neway T, Thibault D, Barrat F, Boulouis H J, Pilet C
Institut d'Immunologie animale et comparée, Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France.
Res Immunol. 1995 Jul-Aug;146(6):363-71. doi: 10.1016/0923-2494(96)81040-6.
Effects of polar glycopeptidolipids of Mycobacterium chelonae (pGPL-Mc) in the in vivo stimulation of haematopoietic growth and differentiation of murine bone marrow and spleen cells was investigated in this study. Progenitors were determined with a quantitative cultural analysis of bone marrow and spleen cells in methylcellulose using rmGM-CSF and rmIL3. Injection of pGPL-Mc produced a significant time-related increase in the number of bone marrow and spleen CFUs. pGPL-Mc treatment, in particular, increased the number of bone marrow and splenic CFU-GMs, CFU-Gs and CFU-Ms during and after three intraperitoneal administrations. The greatest myeloid stimulation of bone marrow CFU-GMs, CFU-Gs and CFU-Ms was observed between days 7 and 14, with maximal values on days 12 and 14. Highly significant stimulation of splenic CFU-GMs, CFU-Gs and CFU-Ms was observed between days 7 and 10 with maximal values on day 10, while the initial stimulation of these progenitors was observed starting from day 1 in bone marrow and day 7 in spleen. These effects of pGPL-Mc were associated with an increase in granulocyte, monocyte and thrombocyte counts in the peripheral blood. Granulocyte and monocyte counts remained high up until day 12, while those of thrombocytes were prolonged until day 18. May-Grünwald-Giemsastained colony samples and differential white blood cell counts demonstrated that the granulocyte population is composed almost entirely of neutrophils. pGPL-Mc is therefore a broad-spectrum haematopoietic growth factor with a highly promising application in the reversal of chemotherapy- and/or radiotherapy-induced myelo-suppression.
本研究调查了龟分枝杆菌的极性糖肽脂（pGPL-Mc）对小鼠骨髓和脾细胞造血生长及分化的体内刺激作用。使用重组人粒细胞-巨噬细胞集落刺激因子（rmGM-CSF）和重组人白细胞介素3（rmIL3），通过甲基纤维素中骨髓和脾细胞的定量培养分析来确定祖细胞。注射pGPL-Mc后，骨髓和脾集落形成单位（CFU）的数量随时间显著增加。特别是在三次腹腔注射期间及之后，pGPL-Mc处理增加了骨髓和脾脏中粒细胞-巨噬细胞集落形成单位（CFU-GMs）、粒细胞集落形成单位（CFU-Gs）和巨噬细胞集落形成单位（CFU-Ms）的数量。在第7天至第14天观察到骨髓CFU-GMs、CFU-Gs和CFU-Ms的最大髓系刺激，在第12天和第14天达到最大值。在第7天至第10天观察到脾脏CFU-GMs、CFU-Gs和CFU-Ms受到高度显著刺激，在第10天达到最大值，而这些祖细胞的初始刺激在骨髓中从第1天开始，在脾脏中从第7天开始。pGPL-Mc的这些作用与外周血中粒细胞、单核细胞和血小板计数的增加有关。粒细胞和单核细胞计数在第12天之前一直保持较高水平，而血小板计数则延长至第18天。May-Grünwald-Giemsa染色的集落样本和白细胞分类计数表明，粒细胞群体几乎完全由中性粒细胞组成。因此，pGPL-Mc是一种广谱造血生长因子，在逆转化疗和/或放疗引起的骨髓抑制方面具有极有前景的应用。
